"Designing Growth Strategies is in our DNA"
The global orphan drugs market size was at USD 125,016.1 Million in 2017 and is projected to reach USD 294,037.8 Million by 2025, exhibiting at a CAGR of 11.4% during the forecast period (2018-2025).
According to the European Organization for Rare Diseases, orphan drugs are produced for diagnosis, prevention, and treatment of rare disorders. The oncology therapy area holds higher orphan drugs market share due to emergence of new cancer-related diseases. Additionally, FDA approvals to a series of cancer-related orphan drugs are expected to result into increased commercialization of orphan drugs, especially oncology therapy areas, during the forecast period.
The market is expected to witness higher demand for immunomodulators, as they regularize or amplify the immune system. Rising prevalence of infectious diseases in developed as well as emerging nations and higher prices of medications are projected to fuel demand for immunomodulators, enabling orphan drugs market growth during the forecast period.
Get comprehensive study about this report by, request a free sample copy
"Higher prevalence of cancer is projected to boost the global market"
Exponentially increasing incidence of cancer is boosting the major market players to develop oncology-related orphan drugs. Moreover, lucrative incentive policies by governments and approvals from FDA and EU regulations are paving way for the entry of new drugs into the orphan drugs Industry. In healthcare space, drugs manufactured for smaller number of patients hold the higher cost as compared to drugs manufactured for larger number of patients, due to which oncology therapy area is projected to accelerate with a considerable pace during the forecast period.
To get details on market share, speak to analyst
Based on the therapy area, the orphan drugs market segments include oncology, haematology, neurology, endocrinology, cardiovascular, respiratory, immunotherapy, and others. Oncology therapy area segment accounted for 49.8% share of market in 2017. In terms of drug type, the market is categorized as biologics and non-biologics. Based on distribution channel, the market segment includes hospital pharmacy, retail pharmacies, online sales, and others.
"High per capita expenditure followed by new FDA approvals to boost market in North America"
North America market generated a revenue of USD 67,144.6 Mn in 2017, and is anticipated to emerge dominant in the orphan drugs market share during the forecast period. North America is expected to witness considerable growth on account of rising government spending on research and development of orphan drugs, extensively accelerated FDA approvals for newly developed drugs, and rising emphasis on implementation of orphan drugs act.
North America Orphan Drugs Market, 2017
To get geographical overview of this market, request a free sample copy
Moreover, incentivisation of orphan drug development as well as enforcement of new marketing authorizations for orphan drugs are anticipated to drive the Europe market. The market growth in Asia Pacific region is likely to nurture at a considerable rate owing to higher prevalence of rare disorders followed by priority for execution of orphan drug legislations in Asian countries.
"Pfizer Inc. & Eli Lily to Account for Considerable Market Share in Terms of Revenue"
The major players operating in the fragmented orphan drugs market are Biogen, Amgen Inc., Actelion Pharmaceuticals Ltd., Eli Lilly and Company, Pfizer Inc., Bayer AG and others. Eli Lily and Pfizer Inc. are expected to hold considerable share in the market. Huge infrastructure in terms of resources and robust distribution network of Pfizer Inc. is anticipated to offer significant share of the global orphan drug market to the company.
Huge investment in research and innovation for new orphan drug development represents considerable opportunity for pharmaceutical manufacturers to register significant share in the global market. Factors such as lucrative incentive policies by governments and approvals from FDA and EU regulations are propelling the entry of new drugs into the orphan drugs industry.
The report provides qualitative and quantitative insights on orphan drugs industry, potential, dynamics, trends and detailed analysis of market size and growth rate for all possible segments in the market. The market is segmented as per therapy area, drug type, distribution channel, and region. On the basis of therapy area, the global market is categorized into oncology, hematology, neurology, endocrinology, cardiovascular, respiratory, immunotherapy, and others.
To get information on various segments, share your queries with us
On the basis of drug type, the market is segmented as biologics and non-biologics. Based on the distribution channel, the global orphan drugs Industry is segmented into hospital pharmacy, retail pharmacy, online sales, and others, Geographically, the market is segmented into four major regions, which are North America, Europe, Asia Pacific, and the rest of the world. The regions are further categorized into countries.
Along with this, the research report includes orphan drugs market potential, dynamics and competitive landscape. Additionally, the report also offers insights on the prevalence of major orphan disease in key countries, pipeline review for orphan drugs, technological developments, and healthcare spending by key countries - 2017.
By Therapy Area
By Drug Type
By Distribution Channel
Based on the detailed study conducted by Fortune Business Insights, the orphan drugs market was valued at USD 125.01 Billion in 2017.
Fortune Business Insights has estimated the orphan drugs market to be valued at USD 294.03 Billion in 2025
The orphan drugs market is projected to grow at a CAGR of 11.4% during the forecast period.
In 2017, North America dominated the orphan drugs market by generating a revenue of USD 67.14 Billion.
Increasing prevalence of caner is driving the growth of global orphan drugs market.
Amgen Inc., Bayer AG and Allergan are the companies that dominated the orphan drugs market in 2017.
Based on the analysis done by Fortune Business Insights, the orphan drugs market is expected to witness a significant growth due to the increasing number of policies by governments and approvals from FDA and EU regulations for orphan drugs which is offering a lucrative opportunity to the market players to enter into the market easily.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm